Originally anchored at the time of start-up in technology licensed from Case Western Reserve University, Sujana Biotech is an early-stage biotech company developing novel therapeutics for a range of inflammatory and vascular disorders. Launched in 2015 by BioMotiv (the mission-driven accelerator) in a partnership with experienced players out of University Hospitals Harrington Heart & Vascular Institute, Cleveland Clinic and Case Western Reserve University), the founders identified a unique binding site on the leukocyte integrin Mac-1 that is responsible for the pathologic recruitment and activation of leukocytes at sites of vascular injury. The companys lead product is in the early preclinical phase of development.
